Stanozolol 50mg/ml
- Home
- Stanozolol 50mg/ml
Description
Formula:
Each ml contains:
Stanozolol…………………………………………………………………………………………… 50 mg.
Excipients…………………………………………………………………………………………………… c.s
Properties:
The active ingredient is stanozolol, which is 17-&-hydroxy-17-&-methyl androstane (3,2-c) pyrazole, a modern anabolic, effective both orally and parenterally, and a powerful stimulant of protein synthesis. The effect of the medicine (which in the case of STANOZOLOL lasts 2 or 3 weeks) manifests itself with an increase in appetite and body weight and with a remarkable recovery of the general condition, improving the use of proteins.
Posology:
STANOZOLOL Intramuscular injection:
Adults: 1 mL every 2 to 3 weeks.
Children: Up to 2 years: 0.5 mL every 2 or 3 weeks.
Children: From 2 to 6 years: from 0.5 to 1 mL every 2 or 3 weeks, at the doctor’s discretion.
It is an oily suspension particularly studied for prolonged absorption without local irritating effects. Its use is preferable whenever the physician deems convenient parenteral administrations spaced in time. It is convenient to integrate the treatment with a rich and balanced diet.
Contraindications:
Hypersensitivity to stanozolol, pregnancy, prostate cancer.
Secundary effects:
Although very rare and always reversible, the following may occur: Nausea, vomiting, excitement, insomnia, acne.
Indications:
States of general decline, thinness of various origins, rebellious anorexia, convalescence, chronic and debilitating illnesses.
Nephrotic syndrome, asthmatics, rheumatoid arthritis, etc., to neutralize the catabolic effect of cortisones.
As an adjunct in the treatment of decubitus wounds, slow healing fractures, osteoporosis, extensive burns, pre and postoperative periods.
In pediatrics, in delayed height and weight growth, in somatic hypoevolutionism, in dystrophies and in immaturity.
interactions:
Concomitant administration of corticosteroids or ACTH may occasionally cause edema. In treatments with anticoagulants, there may be an increase in the response to these drugs, so it may be necessary to reduce their dose to obtain the same therapeutic effect.
Precautions:
In patients sensitive to endocrine or hydroelectrolytic side effects (edema tendency), periodic monitoring is appropriate during prolonged treatments. In patients with liver disease, monitoring of cholestasis indices is recommended.
Poisoning and its treatment:
At the indicated therapeutic doses, acute toxicity is not expected. In case of overdose, go to the Medical Emergency, Toxicology Section.
Presentation:
Box containing 1 vial x 30 mL.
Store at a temperature below 25°C in a dry place and out of reach of children.